Quickly Spot Consensus Among the World’s Best Equity Analysts
| Name | Upside % |
Analysts bullish % |
|
|---|---|---|---|
|
61%
upside
3 price targets
|
0
%
|
|
|
|
61%
upside
3 price targets
|
0
%
|
|
|
|
60%
upside
12 price targets
|
0
%
|
|
|
104
Xeris Biopharma Holdings
XERS
$1.17B
|
60%
upside
4 price targets
|
0
%
|
|
|
59%
upside
3 price targets
|
0
%
|
|
|
|
59%
upside
5 price targets
|
0
%
|
|
|
|
58%
upside
3 price targets
|
0
%
|
|
|
|
58%
upside
3 price targets
|
0
%
|
|
|
|
58%
upside
5 price targets
|
0
%
|
|
|
|
57%
upside
3 price targets
|
0
%
|
|
|
111
Amylyx Pharmaceuticals
AMLX
$1.38B
|
57%
upside
4 price targets
|
0
%
|
|
|
57%
upside
5 price targets
|
0
%
|
|
|
|
56%
upside
5 price targets
|
0
%
|
|
|
|
55%
upside
3 price targets
|
0
%
|
|
|
|
55%
upside
3 price targets
|
0
%
|
|
|
|
54%
upside
4 price targets
|
0
%
|
|
|
|
53%
upside
5 price targets
|
0
%
|
|
|
|
53%
upside
3 price targets
|
0
%
|
|
|
|
53%
upside
3 price targets
|
0
%
|
|
|
|
52%
upside
3 price targets
|
0
%
|
|
|
|
52%
upside
8 price targets
|
0
%
|
|
|
|
51%
upside
5 price targets
|
0
%
|
|
|
|
51%
upside
3 price targets
|
0
%
|
|
|
|
51%
upside
4 price targets
|
0
%
|
|
|
|
50%
upside
3 price targets
|
0
%
|
|